305 related articles for article (PubMed ID: 26097599)
1. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
2. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
4. Genetic variability of DNA repair mechanisms in chemotherapy treatment outcome of gastric cancer patients.
Zhong G; Li HK; Shan T; Zhang N
Genet Mol Res; 2015 Dec; 14(4):17228-34. PubMed ID: 26681216
[TBL] [Abstract][Full Text] [Related]
5. Genetic variability of ERCC1 and ERCC2 influences treatment outcomes in gastric cancer.
Yu WH; Wang YX; Guo JQ; Wang YL; Zheng JS; Zhu KX
Genet Mol Res; 2015 Dec; 14(4):17529-35. PubMed ID: 26782397
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of DNA repair pathways influence the response to chemotherapy and overall survival of gastric cancer.
Zhou J; Liu ZY; Li CB; Gao S; Ding LH; Wu XL; Wang ZY
Tumour Biol; 2015 Apr; 36(4):3017-23. PubMed ID: 25542228
[TBL] [Abstract][Full Text] [Related]
8. Genetic variability of ERCC1 and ERCC2 genes involved in the nucleotide excision repair pathway influences the treatment outcome of gastric cancer.
Zheng DL; Tang GD; Chen YN; Zhang T; Qin MB
Genet Mol Res; 2016 Apr; 15(2):. PubMed ID: 27173253
[TBL] [Abstract][Full Text] [Related]
9. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
[TBL] [Abstract][Full Text] [Related]
10. Genetic variability of ERCC1 genes in NER pathway influences the treatment outcome of gastric cancer.
Bai Y; Wang L; Li G; Fang X; Li Y; Yang S
Int J Clin Exp Pathol; 2015; 8(10):13367-73. PubMed ID: 26722542
[TBL] [Abstract][Full Text] [Related]
11. Association between ERCC1 and ERCC2 gene polymorphisms and chemotherapy response and overall survival in osteosarcoma.
Cao ZH; Yin HP; Jiang N; Yu B
Genet Mol Res; 2015 Aug; 14(3):10145-51. PubMed ID: 26345951
[TBL] [Abstract][Full Text] [Related]
12. Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population.
Qi YJ; Cui S; Yang YZ; Han JQ; Cai BJ; Sheng CF; Ma Y; Wuren T; Ge RL
J Cancer Res Ther; 2013; 9(3):410-5. PubMed ID: 24125975
[TBL] [Abstract][Full Text] [Related]
13. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
[TBL] [Abstract][Full Text] [Related]
14. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 and ERCC2 variants predict survival in gastric cancer patients.
Li Y; Liu Z; Liu H; Wang LE; Tan D; Ajani JA; Wei QY
PLoS One; 2013; 8(9):e71994. PubMed ID: 24023723
[TBL] [Abstract][Full Text] [Related]
16. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
18. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
19. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in ERCC1 and XPF gene and response to chemotherapy and overall survival of non-small cell lung cancer.
Shi ZH; Shi GY; Liu LG
Int J Clin Exp Pathol; 2015; 8(3):3132-7. PubMed ID: 26045829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]